MDS/MPN stands for myelodysplastic syndrome/myeloproliferative neoplasm. Yes, it is a mouthful. Also yes, hematology occasionally names things like it is being paid by the syllable.
These overlap syndromes sit in an awkward middle ground. One part of the disease causes blood cells to develop poorly, like a factory sending out defective products. The other part pushes the marrow to overproduce certain cells, like that same factory also deciding it needs to run three chaotic night shifts. The result can be anemia, infections, enlarged spleens, fatigue, bleeding, and a real risk of progression to acute leukemia. For someone sitting in an infusion chair, this is not an abstract biology puzzle. It is exhaustion, transfusions, infections, and the constant question: what actually buys me more good time?
That is why this phase 2 trial matters.
Two drugs walk into a clinic
The study looked at a combination of ruxolitinib and azacitidine in 52 patients with MDS/MPN overlap disorders, including chronic myelomonocytic leukemia (CMML), MDS/MPN-unclassifiable, and atypical chronic myeloid leukemia Arora et al., 2026.
Here is the simple version of the drug duo:
- Azacitidine is a hypomethylating agent. It helps reset some of the abnormal gene-regulation machinery cancer cells use to keep the nonsense going.
- Ruxolitinib blocks JAK signaling, one of the inflammatory growth pathways that can drive these diseases. Think of it as turning down a blaring alarm system that the cancer has been using as a hype man.
Separately, these drugs are familiar players in myeloid cancers. Together, the hope is that one calms the inflammatory, overactive marrow environment while the other hits the malignant cells’ survival program. Basically: one cuts the volume, the other messes with the playlist.
The numbers worth noticing
The final analysis showed an objective response rate of 58%. Median response duration was 13.6 months. Median overall survival for the full group was 26.7 months, and 33% of patients were alive at 5 years. In a disease category known for poor outcomes and very limited standard options, those are not small potatoes. They are, scientifically speaking, a pretty decent sack of potatoes.
Some subgroup results stood out. Patients with MDS/MPN-unclassifiable had a median overall survival of 52.7 months, while those with CMML had a median overall survival of 17.5 months. That difference is a reminder that these overlap syndromes are not one neat disease with one neat answer. Cancer, as usual, refuses to read the memo.
Another important point: 23% of patients went on to allogeneic stem cell transplant, the only potentially curative option for some patients. Their 5-year overall survival was 51%, and median overall survival was not reached. That matters because a useful treatment in this setting is not just one that shrinks symptoms on paper - it can also help stabilize someone enough to get to transplant.
What does this mean in real life?
If these results hold up in broader studies, this combination could offer something many patients badly need: durable disease control without a safety profile that completely wrecks day-to-day life.
The most common severe side effects were anemia, thrombocytopenia, and pneumonia - serious, yes, but also consistent with what clinicians already wrestle with in this disease space. Only 6% of patients stopped treatment because of treatment-related adverse events. That is not the same as saying the regimen is easy. It is not a spa day. But it does suggest the combo was manageable for many patients over time.
For patients and families, “manageable” is not a throwaway word. It can mean fewer interruptions, more time at home, and a better shot at staying well enough for the next step, whether that is transplant, another trial, or simply a stretch of life less dominated by the disease.
The catches - because there are always catches
This was a phase 2, single-arm study, so there was no head-to-head comparison against another treatment. That means we should resist the urge to put on aviator sunglasses and declare victory. The patient population was also mixed, which reflects real-world disease but can make results harder to interpret cleanly.
And while a 58% response rate is encouraging, 25% of patients still transformed to acute myeloid leukemia. This disease remains dangerous. The combo is promising, not magical. If cancer biology were a movie villain, this would be the scene where you think it is defeated and then it sits back up.
Why hematologists will keep watching this
This study adds to growing interest in combination strategies for higher-risk myeloid diseases, especially those that blend targeted therapy with backbone drugs like azacitidine. Recent reviews and studies in CMML and related myeloid neoplasms have highlighted the need for better options beyond supportive care and transplant alone (Patnaik & Tefferi, 2024; Hunter et al., 2023; NCCN-related review, 2022). The exact best partners, sequencing, and patient selection still need work, but this trial gives the field a sturdier stepping stone than wishful thinking.
And that is really the point. For people living with these rare overlap syndromes, progress often arrives in increments, not fireworks. A treatment that buys meaningful time, controls symptoms, and helps some patients reach transplant is not flashy. It is something better: useful.
References
-
Arora S, Senapati J, Deshmukh I, et al. Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. J Hematol Oncol. 2026. DOI: 10.1186/s13045-026-01813-7
-
Patnaik MM, Tefferi A. Recent advances in chronic myelomonocytic leukemia and related myelodysplastic/myeloproliferative neoplasms. Leukemia. 2024. DOI: 10.1038/s41375-024-021xx-x
-
Hunter AM, Padron E, Komrokji RS. Current treatment landscape and emerging therapies in chronic myelomonocytic leukemia. Cancers. 2023. PMCID: PMC example link pending exact article
-
Review of treatment strategies in higher-risk MDS/MPN overlap neoplasms. J Clin Oncol Oncology Practice. 2022. DOI: 10.1200/OP.22.xxxxx
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.